Analyst Price Targets — VSTM
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| March 5, 2026 3:06 pm | Clara Dong | Jefferies | $19.00 | $6.18 | StreetInsider | Jefferies Reiterates Buy Rating on Verastem (VSTM); "catalyst-rich 2026" |
| February 19, 2026 12:18 pm | — | Mizuho Securities | $18.00 | $5.71 | TheFly | Verastem price target raised to $18 from $15 at Mizuho |
| October 29, 2025 12:51 pm | — | Mizuho Securities | $15.00 | $8.85 | TheFly | Verastem price target raised to $15 from $14 at Mizuho |
| October 21, 2025 2:08 pm | Graig Suvannavejh | Mizuho Securities | $14.00 | $8.12 | StreetInsider | Mizuho Reiterates Outperform Rating on Verastem (VSTM) |
| October 21, 2025 10:48 am | Swayampakula Ramakanth | H.C. Wainwright | $14.00 | $8.02 | StreetInsider | H.C. Wainwright Reiterates Buy Rating on Verastem (VSTM) |
| October 20, 2025 4:16 pm | — | RBC Capital | $13.00 | $8.01 | TheFly | Verastem data 'best-in-class' despite slight decline, says RBC Capital |
| March 24, 2025 11:30 am | Michael Schmidt | Guggenheim | $14.00 | $6.88 | TheFly | Verastem price target raised to $14 from $13 at Guggenheim |
| March 24, 2025 10:09 am | — | H.C. Wainwright | $10.00 | $6.88 | TheFly | Verastem price target raised to $10 from $7 at H.C. Wainwright |
| July 29, 2024 7:15 am | Graig Suvannavejh | Mizuho Securities | $7.00 | $2.77 | StreetInsider | Verastem (VSTM) PT Lowered to $7 at Mizuho |
| May 24, 2024 12:29 pm | Justin Zelin | BTIG | $13.00 | $4.12 | StreetInsider | Verastem (VSTM) PT Lowered to $13 at BTIG |
Latest News for VSTM
BOSTON--(BUSINESS WIRE)--Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK pathway-driven cancers, today announced two-year median follow-up data from the Phase 2 RAMP 201 clinical trial that evaluated AVMAPKI® FAKZYNJA® combination therapy (avutometinib capsules; defactinib tablets) in patients with recurrent low-grade serous ovarian cancer…
SG Americas Securities LLC increased its position in shares of Verastem, Inc. (NASDAQ: VSTM) by 3,333.8% in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 390,325 shares of the biopharmaceutical company's stock after purchasing an additional 378,958 shares during the quarter.
BOSTON--(BUSINESS WIRE)--Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK pathway-driven cancers, today announced the grant of 141,000 restricted stock units to eleven new employees. The awards were granted pursuant to the Nasdaq inducement grant exception as an inducement material to the employee's acceptance of employment with Verastem…
Oncology is evolving fast as immunotherapy, AI and targeted drugs expand treatment options, boost outcomes, and fuel long-term healthcare growth.
Verastem (VSTM) maintains a "Buy" rating, driven by progress in KRAS G12D-targeted therapies and multiple 2026 catalysts. Company received FDA guidance to initiate registration-directed phase 2 trials for VS-7375 in KRAS G12D-mutated PDAC, NSCLC, and CRC. Upcoming 2026 milestones include pivotal data from RAMP 205 [PDAC], long-term RAMP 201 [LGSOC] results, and early VS-7375 data.
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for VSTM.
U.S. House Trading
No House trades found for VSTM.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.